Cargando…

Danhong Injection Price Trend and Its Utilization by Coronary Heart Disease Patients: Evidence From Hospital Records in China

Background: Danhong injection (DHI) accounts for the highest proportion of drug costs for inpatients with coronary heart disease (CHD). However, if DHI price influences utilization remains unclear. Objective: The objective was to compare changes in the use of DHI for CHD patients during three stages...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Liming, Xu, Yue, Su, Zihan, Man, Xiaowei, Jiang, Yan, Zhao, Liying, Cheng, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114504/
https://www.ncbi.nlm.nih.gov/pubmed/35600876
http://dx.doi.org/10.3389/fphar.2022.857167
_version_ 1784709791143165952
author Liu, Liming
Xu, Yue
Su, Zihan
Man, Xiaowei
Jiang, Yan
Zhao, Liying
Cheng, Wei
author_facet Liu, Liming
Xu, Yue
Su, Zihan
Man, Xiaowei
Jiang, Yan
Zhao, Liying
Cheng, Wei
author_sort Liu, Liming
collection PubMed
description Background: Danhong injection (DHI) accounts for the highest proportion of drug costs for inpatients with coronary heart disease (CHD). However, if DHI price influences utilization remains unclear. Objective: The objective was to compare changes in the use of DHI for CHD patients during three stages after two comprehensive reforms of public hospitals in Beijing. These findings will provide support for controlling the drug burden of CHD patients and regulating drug use behavior. Research Design: CHD diagnosis and treatment data were extracted from the Hospital Information System (HIS) of 33 public hospitals. Patients were grouped according to different treatment methods and clinical classifications. Changes in the utilization of DHI, including the use rate (the percentage of CHD patients using DHI), number of prescribed units (average number of units of DHI prescribed per hospital stay), and cost of DHI per hospital stay (equal to the unit price multiplied by the number of prescribed units) between the three stages were statistically analyzed. Association rules were applied to identify changes in drug combinations. Results: After the two reforms, the unit price of DHI dropped from $6.46 to $5.61. At the same time, the use rate increased from 20.77 to 24.00%, the number of prescribed units dropped from 29.76 to 29.21, and the cost of DHI per hospital stay dropped from $192.12 to $163.96. The changes in the use rate and number of prescribed units varied among patients with different clinical types and treatment methods, and the cost of CHI per hospital stay was consistent with the overall situation. The variety of drugs used in combination with DHI remained relatively stable. Conclusion: The use rate of DHI for CHD patients increased, indicating increased applications of DHI in clinical practice. Due to the drop in price, the cost of using DHI decreased, and the financial burden of this drug was reduced.
format Online
Article
Text
id pubmed-9114504
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91145042022-05-19 Danhong Injection Price Trend and Its Utilization by Coronary Heart Disease Patients: Evidence From Hospital Records in China Liu, Liming Xu, Yue Su, Zihan Man, Xiaowei Jiang, Yan Zhao, Liying Cheng, Wei Front Pharmacol Pharmacology Background: Danhong injection (DHI) accounts for the highest proportion of drug costs for inpatients with coronary heart disease (CHD). However, if DHI price influences utilization remains unclear. Objective: The objective was to compare changes in the use of DHI for CHD patients during three stages after two comprehensive reforms of public hospitals in Beijing. These findings will provide support for controlling the drug burden of CHD patients and regulating drug use behavior. Research Design: CHD diagnosis and treatment data were extracted from the Hospital Information System (HIS) of 33 public hospitals. Patients were grouped according to different treatment methods and clinical classifications. Changes in the utilization of DHI, including the use rate (the percentage of CHD patients using DHI), number of prescribed units (average number of units of DHI prescribed per hospital stay), and cost of DHI per hospital stay (equal to the unit price multiplied by the number of prescribed units) between the three stages were statistically analyzed. Association rules were applied to identify changes in drug combinations. Results: After the two reforms, the unit price of DHI dropped from $6.46 to $5.61. At the same time, the use rate increased from 20.77 to 24.00%, the number of prescribed units dropped from 29.76 to 29.21, and the cost of DHI per hospital stay dropped from $192.12 to $163.96. The changes in the use rate and number of prescribed units varied among patients with different clinical types and treatment methods, and the cost of CHI per hospital stay was consistent with the overall situation. The variety of drugs used in combination with DHI remained relatively stable. Conclusion: The use rate of DHI for CHD patients increased, indicating increased applications of DHI in clinical practice. Due to the drop in price, the cost of using DHI decreased, and the financial burden of this drug was reduced. Frontiers Media S.A. 2022-05-04 /pmc/articles/PMC9114504/ /pubmed/35600876 http://dx.doi.org/10.3389/fphar.2022.857167 Text en Copyright © 2022 Liu, Xu, Su, Man, Jiang, Zhao and Cheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Liming
Xu, Yue
Su, Zihan
Man, Xiaowei
Jiang, Yan
Zhao, Liying
Cheng, Wei
Danhong Injection Price Trend and Its Utilization by Coronary Heart Disease Patients: Evidence From Hospital Records in China
title Danhong Injection Price Trend and Its Utilization by Coronary Heart Disease Patients: Evidence From Hospital Records in China
title_full Danhong Injection Price Trend and Its Utilization by Coronary Heart Disease Patients: Evidence From Hospital Records in China
title_fullStr Danhong Injection Price Trend and Its Utilization by Coronary Heart Disease Patients: Evidence From Hospital Records in China
title_full_unstemmed Danhong Injection Price Trend and Its Utilization by Coronary Heart Disease Patients: Evidence From Hospital Records in China
title_short Danhong Injection Price Trend and Its Utilization by Coronary Heart Disease Patients: Evidence From Hospital Records in China
title_sort danhong injection price trend and its utilization by coronary heart disease patients: evidence from hospital records in china
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114504/
https://www.ncbi.nlm.nih.gov/pubmed/35600876
http://dx.doi.org/10.3389/fphar.2022.857167
work_keys_str_mv AT liuliming danhonginjectionpricetrendanditsutilizationbycoronaryheartdiseasepatientsevidencefromhospitalrecordsinchina
AT xuyue danhonginjectionpricetrendanditsutilizationbycoronaryheartdiseasepatientsevidencefromhospitalrecordsinchina
AT suzihan danhonginjectionpricetrendanditsutilizationbycoronaryheartdiseasepatientsevidencefromhospitalrecordsinchina
AT manxiaowei danhonginjectionpricetrendanditsutilizationbycoronaryheartdiseasepatientsevidencefromhospitalrecordsinchina
AT jiangyan danhonginjectionpricetrendanditsutilizationbycoronaryheartdiseasepatientsevidencefromhospitalrecordsinchina
AT zhaoliying danhonginjectionpricetrendanditsutilizationbycoronaryheartdiseasepatientsevidencefromhospitalrecordsinchina
AT chengwei danhonginjectionpricetrendanditsutilizationbycoronaryheartdiseasepatientsevidencefromhospitalrecordsinchina